For Immediate Release

Chicago, IL – June 24, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tiffany (TIF), Big Lots (BIG), Family Dollar (FDO), Isis Pharmaceuticals (ISIS) and OncoGenex (OGXI).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

Long-Term Job Stagnation

The two major forces behind the secular slowdown in job creation have been automation and globalization (off-shoring). It would not be particularly wise to reverse job losses coming from automation, since technology is the source of productivity growth and ultimately higher standards of living.

On the other hand, that model will not work to well if there are no jobs as a result. What will happen is that there will be a further hollowing out of the middle class, with a few extremely rich people and many who are struggling to make ends meet, and a growing number in real poverty.

This suggests that we will have sort of a bar-bell economy — with strong firms that cater to the carriage trade, for example Tiffany’s (TIF) and Neiman Marcus, as well as inferior goods firms that do well such as Big Lots (BIG) and Family Dollar (FDO). Firms in the middle will suffer.

Isis Generating Impressive Data

At perhaps the two biggest industry trade conferences of the year, the American Society of Clinical Oncology (ASCO) and the American Diabetes Association (ADA), Isis Pharmaceuticals (ISIS) and/or its partners presented encouraging pre-clinical and early-stage clinical data showing the potenital power of antisense technology as a new paradigm for treating cancer and diabetes — two of the most widespread diseases in the U.S. and worldwide.

Specifically, at the ASCO meeting in early June, Isis and/or its partners held 4 presentations on oncology candidates using Isis’ technology. Specifically, OncoGenex (OGXI) presented data from 2 phase II programs with OGX-011 that demonstrated very encouraging data. In a phase II program, patients with advanced metastatic prostate cancer were randomized to receive OGX-011 plus docetaxel or docetaxel alone.

The median overall survival (OS) for the OGX-011 plus docetaxel group was 23.8 months, vs. 16.9 months with docetaxel alone. This corresponded to a 39% reduction in the rate of death over the study period. OncoGenex hopes to secure a partnership for OGX-011 and move into a phase III program shortly.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/ZacksInvestment

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Zacks Investment Research

Last 5 posts by Zacks Market Commentaries

• CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
• Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
• Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
• Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
• GameStop Meets Expectations - Analyst Blog - November 20th, 2009